Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Orthocell Ltd ( (AU:OCC) ) has shared an update.
Orthocell Limited has increased its equity stake in Marine Biomedical Pty Ltd to 12%, securing global distribution rights for PearlBone™, an innovative bone substitute made from sustainably sourced pearl shells. This strategic investment enhances Orthocell’s regenerative medicine portfolio and positions the company to capitalize on the US$1.6 billion bone substitute market, with expectations of significant value growth following regulatory approvals.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company specializing in biologically driven solutions for nerve, tendon, and bone repair. The company focuses on leveraging its established distribution networks, particularly in the United States, to deliver innovative medical products to the market.
Average Trading Volume: 633,878
Technical Sentiment Signal: Buy
Current Market Cap: A$324.7M
See more insights into OCC stock on TipRanks’ Stock Analysis page.